Paper 85 - BREAKING HLA RESTRICTION TO THERAPEUTICALLY TARGET A FUSION-DERIVED PUBLIC NEOANTIGEN IN DESMOPLASTIC SMALL ROUND CELL TUMOR

Author(s)

• 

  Lauren Banks, MD, PhD (she/her/hers)

  Assistant Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States

  Slides

Co-Author(s)

• HA

  Hannah Arkin, n/a

  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• SC

  Smita Chandran, Ph.D.

  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• ES

  Emily K. Slotkin, MD

  Assistant Attending Pediatrician
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• 

  Madelyn Espinosa-Cotton, PhD

  Senior Research Scientist
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• NS

  Neerav Shukla, M.D.

  Chief, Pediatric Translational Medicine Service
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• LM

  Luc Morris, M.D.

  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• ML

  Marc Ladanyi, M.D.

  Chief, Molecular Diagnostics Service
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• AK

  Andrew Kung, MD, PhD

  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• MK

  Martin Klatt, M.D.

  Charité University Medicine
  Berlin, Brandenburg, Germany
• 

  Christopher Klebanoff, MD

  Associate Attending Physician
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• DD

  Dylan Domenico

  Department of Pediatrics and Computational Oncology, Department of Epidemiology & Biostatistics
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• EP

  Elli Papaemmanouil

  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• GG

  Gunes Gundem

  Memorial Sloan Kettering Cancer Center
  New York, New York, United States